Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Luckily for you, we built StockStory to help you separate the good from the bad. That said, here are three cash-producing companies to steer clear of and a few better alternatives.
America's Car-Mart (CRMT)
Trailing 12-Month Free Cash Flow Margin: 13.8%
With a strong presence in the Southern and Central US, America’s Car-Mart (NASDAQ: CRMT) sells used cars to budget-conscious consumers.
Why Do We Pass on CRMT?
- Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
- Issuance of new shares over the last three years caused its earnings per share to fall by 92.3% annually, even worse than its revenue declines
- Unprofitable operations could lead to additional rounds of dilutive equity financing if the credit window closes
At $1.01 per share, America's Car-Mart trades at 24.6x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than CRMT.
Campbell's (CPB)
Trailing 12-Month Free Cash Flow Margin: 7%
With its iconic canned soup as its cornerstone product, Campbell's (NASDAQ: CPB) is a packaged food company with an illustrious portfolio of brands.
Why Is CPB Risky?
- Shrinking unit sales over the past two years indicate demand is soft and that the company may need to revise its product strategy
- Projected sales decline of 2.9% for the next 12 months points to a tough demand environment ahead
- Incremental sales over the last three years were much less profitable as its earnings per share fell by 10.2% annually while its revenue grew
Campbell’s stock price of $19.33 implies a valuation ratio of 11.6x forward P/E. Read our free research report to see why you should think twice about including CPB in your portfolio.
GoodRx (GDRX)
Trailing 12-Month Free Cash Flow Margin: 25.1%
Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ: GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.
Why Do We Think GDRX Will Underperform?
- Sales were flat over the last two years, indicating it’s failed to expand this cycle
- Smaller revenue base of $785.2 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
GoodRx is trading at $3.41 per share, or 9.9x forward P/E. Check out our free in-depth research report to learn more about why GDRX doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
